Drug intelligence / Profile preview

CSI103

Development stage: Preclinical
Lead developer: Curigin
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
Administration: Parenteral

Overview

CSI103 (Csi103) is a bispecific small interfering RNA (siRNA) gene therapy being developed by Curigin for the treatment of hyperlipidemia, dyslipidemia, and obesity. Utilizing a non-viral delivery system, CSI103 is designed to simultaneously target and silence the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) and apolipoprotein C-III (APOC3), two key regulators of lipid metabolism. By inhibiting these targets, the therapy aims to lower low-density lipoprotein cholesterol (LDL-C) and triglyceride levels. CSI103 is currently in preclinical development.

Targets

APOC3 (Apolipoprotein C-III)PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on CSI103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSI103.

Explore the full profile